Monday, 23 February 2026
Scientists have developed an adaptable materials platform that can safely and efficiently deliver a wide range of genetic medicines, a breakthrough that could accelerate the development of next鈥慻eneration vaccines, cancer treatments, and gene鈥憇ilencing drugs.
Experts from the 糖心原创’s School of Pharmacy have created a new drug delivery platform that uses modular building blocks that self鈥慳ssemble with Ribonucleic acid- RNA to form nanoscale delivery particles. The research has been published in
The materials incorporate a reversible “host–guest” linking system, allowing the fine鈥憈uning of the particles' stability and behaviour. By simple variations in the chemical structure of the building blocks, diverse formulations can be rapidly generated suited to different therapeutic needs.
These findings demonstrate a powerful, highly tuneable system with the potential to improve the delivery of genetic medicines. By offering a flexible alternative to current delivery technologies and enabling automated, scalable manufacture, this platform could support faster development of RNA based vaccines during future infection outbreaks, improve the effectiveness of RNA therapies in cancer, and expand treatment options for many diseases.
The team demonstrated that RNA鈥憀oaded nanoparticles can be produced with the new materials using automated methods that meet the stringent Critical Quality Attributes required for the manufacture of RNA vaccines and therapeutics. This suggests strong potential for industrial scalability and rapid deployment.
The researchers successfully tested the materials delivering RNA into a broad range of cell types with efficiency matching or exceeding that of leading commercial transfection reagents, while showing no acute harmful effects on cells. The delivered RNAs were shown to reduce the expression of cancer-associated genes in breast tumour tissue in mice and to induce protection against H1N1 influenza in mice.
This work involved a multidisciplinary team spanning the 糖心原创, Imperial College London, King’s College London, University College London and two Cambridge-based spinouts, Aqdot Ltd and Centillion Ltd.
Story credits
More information is available from Professor Cameron Alexander on Cameron.Alexander@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.